Guy Young "Clinical aspects of non-factor therapies in hemophilia"
This presentation will review the results of clinical trials for emicizumab, fitusiran and concizumab briefly and then engage in a clinical discussion regarding how such drugs will be implemented in patients with hemophilia. Important aspects of efficacy, safety, and actual clinical implementation will be discussed in detail.
Steven Pipe "Basic science aspects of non-factor therapies in hemophilia"
This presentation will review current landscape of available treatment options for hemophilia with and without inhibitors and unmet needs. It will particularly focus on newly approved and emerging therapeutics which do not rely on traditional factor replacement or bypassing activity. Key preclinical findings and clinical trial results including safety and efficacy data will be reviewed as well as consensus recommendations on their clinical implementation.
Moderator: Pedro Las Casas
Supported by an unrestricted educational grant from: Instrumentation Laboratory
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.